U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07358377) titled 'To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor' on Dec. 28, 2025.
Brief Summary: To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.
Study Start Date: March 15
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: HRS-6209 Capsules and fulvestrant injection
HRS-6209, 100mg BID for 4 weeks, and single dose of fulvestrant injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Atridia Pty Ltd.
Disclaimer: Curated by HT Syndication....